Small molecular weight protein-protein interaction antagonists -: an insurmountable challenge?

被引：99

作者：

Doemling, Alexander ^{[1
,2
]}

机构：

[1] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA

[2] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2008年 / 12卷 / 03期

关键词：

D O I：

10.1016/j.cbpa.2008.04.603

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Several years ago small molecular weight protein-protein interaction (PPI) antagonists were considered as the Mount Everest in drug discovery and generally regarded as too difficult to be targeted. However, recent industrial and academic research has produced a great number of new antagonists of diverse PPIs. This review structurally analyses small molecular weight PPI antagonists and their particular targets as well as tools to discover such compounds. Besides general discussions there will be a focus on the PPI p53/mdm2.

引用

页码：281 / 291

页数：11

共 45 条

[11] NMR structure of a complex between MDM2 and a small molecule inhibitor
Fry, DC
Emerson, SD
Palme, S
Vu, BT
Liu, CM
Podlaski, F
[J]. JOURNAL OF BIOMOLECULAR NMR, 2004, 30 (02) : 163 - 173
[12] A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells
Galatin, PS
Abraham, DJ
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (17) : 4163 - 4165
[13] Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
Grasberger, BL
Lu, TB
Schubert, C
Parks, DJ
Carver, TE
Koblish, HK
Cummings, MD
LaFrance, LV
Milkiewicz, KL
Calvo, RR
Maguire, D
Lattanze, J
Franks, CF
Zhao, SY
Ramachandren, K
Bylebyl, GR
Zhang, M
Manthey, CL
Petrella, EC
Pantoliano, MW
Deckman, IC
Spurlino, JC
Maroney, AC
Tomczuk, BE
Molloy, CJ
Bone, RF
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) : 909 - 912
[14] Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction
Hardcastle, IR
Ahmed, SU
Atkins, H
Calvert, AH
Curtin, NJ
Farnie, G
Golding, BT
Griffin, RJ
Guyenne, S
Hutton, C
Källbad, P
Kemp, SJ
Kitching, MS
Newell, DR
Norbedo, S
Northen, JS
Reid, RJ
Saravanan, K
Willems, HMG
Lunec, J
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) : 1515 - 1520
[15] Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
Issaeva, N
Bozko, P
Enge, M
Protopopova, M
Verhoef, LGGC
Masucci, M
Pramanik, A
Selivanova, G
[J]. NATURE MEDICINE, 2004, 10 (12) : 1321 - 1328
[16] Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
Koblish, HK
Zhao, SY
Franks, CF
Donatelli, RR
Tominovich, RM
LaFrance, LV
Leonard, KA
Gushue, JM
Parks, DJ
Calvo, RR
Milkiewicz, KL
Marugán, JJ
Raboisson, P
Cummings, MD
Grasberger, BL
Johnson, DL
Lu, TB
Molloy, CJ
Maroney, AC
[J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (01) : 160 - 169
[17] NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
Krajewski, M
Ozdowy, P
D'Silva, L
Rothweiler, U
Holak, TA
[J]. NATURE MEDICINE, 2005, 11 (11) : 1135 - 1136
[18] Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents
Kumar, SK
Hager, E
Pettit, C
Gurulingappa, H
Davidson, NE
Khan, SR
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (14) : 2813 - 2815
[19] Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
Kussie, PH
Gorina, S
Marechal, V
Elenbaas, B
Moreau, J
Levine, AJ
Pavletich, NP
[J]. SCIENCE, 1996, 274 (5289) : 948 - 953
[20] Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1α and Hdm2
LaRusch, Gretchen A.
Jackson, Mark W.
Dunbar, James D.
Warren, Robert S.
Donner, David B.
Mayo, Lindsey D.
[J]. CANCER RESEARCH, 2007, 67 (02) : 450 - 454

← 1 2 3 4 5 →